Could a simple asthma drug prevent a dangerous immunotherapy side effect?
NCT ID NCT06860542
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This study tests whether a year of inhaled budesonide (a common asthma medication) can prevent lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently recovered from checkpoint inhibitor pneumonitis will receive either inhaled budesonide plus standard care or standard care alone. The goal is to reduce the need for strong oral or IV steroids and improve quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE-RELATED ADVERSE EVENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITINGCalgary, Alberta, T2N 5G2, Canada
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.